WallStreetZenWallStreetZen

NASDAQ: ELYM
Eliem Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ELYM earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$35.1M
Current Profit Margin
0%

ELYM Return on Equity

Current Company
-31.4%
Current Industry
-63.5%
Current Market
188%
ELYM's Return on Equity (-31.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ELYM announces earnings.

ELYM Return on Assets

Current Company
-30.4%
Current Industry
2.9%
ELYM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ELYM Return on Capital Employed

Current Company
-32.63%
Current Industry
19.5%
ELYM has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ELYM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ELYM$0.00-$34.71M-$35.12MN/AN/A
ANIX$210.00k-$10.70M-$10.74M-28.36%N/A
BLUE$21.73M-$95.08M-$91.17M-11.27%N/A
VIGL$0.00-$80.88M-$82.64MN/AN/A
CLSD$8.23M-$32.42M-$32.49M+207.34%N/A
View Top Biotech Stocks

ELYM earnings dates

Next earnings date
May 13, 2024

Eliem Therapeutics Earnings & Revenue FAQ

What were ELYM's earnings last quarter?

On Invalid Date, Eliem Therapeutics (NASDAQ: ELYM) reported Q4 2023 earnings per share (EPS) of -$0.13, up 55.17% year over year. Total Eliem Therapeutics earnings for the quarter were -$3.64 million. In the same quarter last year, Eliem Therapeutics's earnings per share (EPS) was -$0.29.

If you're new to stock investing, here's how to buy Eliem Therapeutics stock.

What was ELYM's earnings growth in the past year?

As of Q2 2024, Eliem Therapeutics's earnings has grown year over year. Eliem Therapeutics's earnings in the past year totalled -$35.12 million.

What is ELYM's earnings date?

Eliem Therapeutics's earnings date is Invalid Date. Add ELYM to your watchlist to be reminded of ELYM's next earnings announcement.

What was ELYM's revenue last quarter?

On Invalid Date, Eliem Therapeutics (NASDAQ: ELYM) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Eliem Therapeutics's revenue was $0.00.

What was ELYM's revenue growth in the past year?

As of Q2 2024, Eliem Therapeutics's revenue has grown null year over year. Eliem Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.